Your Health, We Care

Home > Photo Wall > Honor and qualification

Venetoclax Production Approval

Release date: 2024-07-10 15:10:31     Recommended: 134

09L1009_23 维奈托克 批文_00.jpg

Venetoclax is a BCL-2 inhibitor used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as well as acute myeloid leukemia (AML). Venetoclax selectively inhibits the anti apoptotic protein BCL-2, which is overexpressed in chronic lymphocytic leukemia (CLL) cells and acute myeloid leukemia (AML) cells. BCL-2 mediates tumor cell survival and is associated with chemotherapy resistance. Venetoclax directly binds to BCL-2 protein, replacing pro apoptotic proteins and restoring the apoptotic process.

Company News

Research News

Drug news